Final Program

318 TUESDAY • MAY 17
C89
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
EMERGING IMMUNE FUNCTIONS OF THE
PULMONARY EPITHELIUM IN INFECTION, ASTHMA,
AND CHRONIC LUNG DISEASE
Assemblies on Allergy, Immunology and Inflammation; Microbiology,
Tuberculosis and Pulmonary Infections; Respiratory Cell and Molecular
Biology; Respiratory Structure and Function
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)
Target Audience
Basic, translational, and clinical researchers interested in advancing their
understanding of how the respiratory epithelium contributes to immunity,
inflammation, and disease.
Objectives
At the conclusion of this session, the participant will be able to:
• learn cutting edge findings on how airway and alveolar epithelia coordinate
inflammatory and immune responses in the lung;
• learn new techniques for targeted study of epithelial cells in the lung;
• appreciate the role of the airway epithelial basal cell in lung repair and
regeneration in health and disease.
Emerging literature has begun to reveal a remarkable number of roles for the
respiratory epithelium, from conducting airway to alveolus, in innate and
adaptive immunity. Far from housekeeping cells that form a simple mechanical
barrier, epithelial cells are increasingly recognized in a new light as professional
immune sentinels that instruct hematopoietic cells and also promote repair
during infection, asthma, fibrosis, and other disorders. This session brings
together leading experts to discuss recent paradigm shifting findings on the
respiratory epithelium as a master regulator of the inflammatory, immune,
fibrotic, and repair processes that underlie both acute and chronic lung disease.
Chairing: M.B. Fessler, MD, Research Triangle Park, NC
A.A. Humbles, PhD, Gaithersburg, MD
2:15 Transcriptional Regulation of Epithelial Biology and Its
Contributions to Lung Disease
J.A. Whitsett, MD, Cincinnati, OH
2:35 Novel Immune Functions of the Alveolar Epithelium During
Pneumonia
J.P. Mizgerd, ScD, Boston, MA
2:55 Role of MUC5B in Pulmonary Fibrosis and Beyond
D.A. Schwartz, MD, Aurora, CO
3:15 Epithelial Cytokines in Allergic Pulmonary Inflammation
C.M. Lloyd, PhD, London, United Kingdom
3:35 Regulation of Airway Basal Stem Cell Self-Renewal in Health
and Disease
B. Gomperts, MD, Los Angeles, CA
3:55 Running Interference: The Lung Epithelium as Orchestrator of
the Interferon Response
A.S. Prince, MD, New York, NY
There will be a 5-minute discussion after each talk.
C90
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
IT TAKES TWO TO TANGO: RIGHT AND LEFT
VENTRICLE INTERACTIONS IN PULMONARY
VASCULAR DISEASE
Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care;
Respiratory Cell and Molecular Biology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 3010/3012 (West Building, Level 3)
Target Audience
Basic, translational and clinical researchers interested in right and left ventricular
function in health and disease.
Clinicians (especially internists, pulmonologists/ intensivists, and cardiologists)
interested in RV and LV function as well as in RV-directed therapies in
pulmonary vascular diseases.
Objectives
At the conclusion of this session, the participant will be able to:
• understand differences and similarities between the RV and LV
• identify the interplay between RV and LV function in health and disease
• understand how research and therapeutic approaches to LV disease can be
translated to RV disease
This session will focus on interactions between the right ventricle (RV) and left
ventricle (LV) in pulmonary hypertension (PH). While it has long been known
that the RV is at risk for failing in PH, little is known about how PH and RV
dysfunction affect the LV. Similarly, the potential effect of PH-specific therapies
on LV function has been poorly understood. Lastly, the exact mechanisms of
RV dysfunction in LV disease are only incompletely understood. This session
will address these knowledge gaps by providing novel evidence indicating that
complex RV and LV interactions
underlie the pathophysiology of decreased cardiac output in PH. Novel and
emerging approaches in LV research and their implications for the study of the
RV will be discussed.
Chairing: T. Lahm, MD, Indianapolis, IN
C.E. Ventetuolo, MD, MS, Providence, RI
W.M. Kuebler, MD, PhD, Toronto, Canada
2:15 RV and LV: Twins or Strangers?
T. Lahm, MD, Indianapolis, IN
2:39 RV Involvement in LV Disease: What Makes the RV Fail in the
Setting of LV Failure?
R. Tedford, MD, Baltimore, MD
3:03 Relax! RV and LV Diastology in Pulmonary Hypertension
F. De Man, PhD, Amsterdam, Netherlands
3:27 Left, Right, or Both? Is There a Role for Beta Blockers, ACE
Inhibitors, or Neurohormonal Modulators in RV Failure?
C.E. Ventetuolo, MD, MS, Providence, RI
3:51 Lessons Learned from Left Heart Failure: Which Novel
Approaches and Directions in LV Research Can Be Applied
to the RV?
M. Bristow, MD, PhD, Denver, CO
ATS 2016 • San Francisco